Latest Health News
Press release: Availability of the Q3 2025 Aide mmoire
Availability of the Q3 2025 Aide mémoire Paris, France – September 24,…
Labviva Kicks Off Smart Lab of the Future Tour
BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Labviva, the leading AI-powered procurement…
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR A conference call will…
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE Rollout
Ad hoc announcement pursuant to Art. 53 LR Highlights: Santhera secures approximately…
PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes
Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable…
Carlsmed, Inc. Selected for Inclusion in Russell 2000 Index
September 22, 2025 09:00 ET | Source: Carlsmed CARLSBAD, Calif., Sept. 22,…
AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE…
Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94%…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
